PROPERTY, PLANT AND EQUIPMENT

12 Months Ended

Apr. 01, 2017

Property, Plant and Equipment [Abstract]

Property and equipment consisted of the following:



(In thousands)	April 1, 2017			April 2, 2016
Land	$	7,389		$	7,905
Building and building improvements	109,933			117,132
Plant equipment and machinery	253,693			238,549
Office equipment and information technology	129,753			127,019
Haemonetics equipment	306,714			295,853
Total	807,482			786,458
Less: accumulated depreciation and amortization	(483,620		)	(448,824		)
Property, plant and equipment, net	$	323,862		$	337,634

During fiscal 2017, we impaired $13.3 million of property, plant and equipment as a result of our review of non-core and underperforming assets and our decision to discontinue the use of and investment in certain assets, of which $0.8 million was included within impairment of assets on the consolidated statements of (loss) income and the remaining $12.5 million was included within cost of goods sold. These impairments impacted Americas Blood Center and Hospital, North America Plasma and EMEA segments by $10.6 million, $1.7 million and $1.0 million, respectively.

During fiscal 2016, we impaired $9.1 million of property, plant and equipment as a result of our global strategic review, of which $6.9 million was included within impairment of assets on the consolidated statements of (loss) income and the remaining $2.2 million was included within cost of goods sold. These impairments impacted our Americas Blood Center and Hospital and EMEA segments by $3.0 million and $6.1 million, respectively.

Depreciation expense was $66.5 million and $56.8 million in fiscal 2017 and fiscal 2016, respectively, which includes $10.0 million and $0.8 million, respectively, of additional depreciation expense due to asset impairments. Depreciation expense was $52.6 million for fiscal 2015.